BioHarvest Sciences Inc.
Description
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
About
CEO
Employees
0
Instrument type
Common Stock
Sector
Industry
MIC code
XNMS
Address
1140-625 Howe Street, Vancouver, BC V6C 2T6, Canada
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 25, 2025 | — | — | — | — |
| Aug 27, 2025 | — | — | — | — |
| May 28, 2025 | — | — | — | — |
| Apr 28, 2025 | — | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 3 |
| Average estimate | — | -0.09 | — | -0.21 |
| Low estimate | — | -0.09 | — | -0.36 |
| High estimate | — | -0.08 | — | -0.09 |
| Last year EPS | — | — | — | -0.78 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
72.650%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | 12.67M |
| Cost of revenue | 7.04M |
| Gross profit | 5.63M |
| Operating expense | |
| Research & development | 3.37M |
| Selling general and admin | 12.07M |
| Other operating expenses | — |
| Operating income | -9.97M |
| Non operating interest income | |
| Income | — |
| Expense | 1.96M |
| Other income expense | -501,000 |
| Pretax income | -12.56M |
| Tax provision | — |
| Net income | -12.56M |
| Basic EPS | -1.05 |
| Diluted EPS | -1.05 |
| Basic average shares | 13.53M |
| Diluted average shares | 13.53M |
| EBITDA | -9.26M |
| Net income from continuing op. | -12.56M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total assets | 15.00M |
| Current assets | |
| Cash | — |
| Cash equivalents | — |
| Cash and cash equivalents | 5.36M |
| Other short term investments | — |
| Accounts receivable | 808,000 |
| Other receivables | 149,000 |
| Inventory | 2.47M |
| Prepaid assets | 274,000 |
| Restricted cash | — |
| Assets held for sale | — |
| Hedging assets | — |
| Other current assets | — |
| Non current assets | |
| Properties | 4.16M |
| Land and improvements | — |
| Machinery furniture equipment | 218,000 |
| Construction in progress | — |
| Leases | 571,000 |
| Accumulated depreciation | -3.31M |
| Goodwill | — |
| Investment properties | — |
| Financial assets | — |
| Intangible assets | — |
| Investments and advances | — |
| Other non current assets | 179,000 |
| Total liabilities | 29.86M |
| Current liabilities | |
| Accounts payable | 1.78M |
| Accrued expenses | 458,000 |
| Short term debt | 20.92M |
| Deferred revenue | 718,000 |
| Tax payable | — |
| Pensions | 958,000 |
| Other current liabilities | 526,000 |
| Non current liabilities | |
| Long term debt | 1.43M |
| Provision for risks and charges | — |
| Deferred liabilities | — |
| Derivative product liabilities | — |
| Other non current liabilities | 1.96M |
| Shareholders equity | |
| Common stock | 68.65M |
| Retained earnings | -83.51M |
| Other shareholders equity | — |
| Total shareholders equity | -14.85M |
| Additional paid in capital | — |
| Treasury stock | — |
| Minority interest | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -12.56M |
| Depreciation | 840,000 |
| Deferred Taxes | — |
| Stock-Based Compensation | 563,000 |
| Other Non-Cash Items | 866,000 |
| Accounts Receivable | -22,000 |
| Accounts Payable | — |
| Other Assets & Liabilities | -1.09M |
| Operating Cash Flow | -11.41M |
| Investing Activities | |
| Capital Expenditures | -1.47M |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -1.47M |
| Financing Activities | |
| Long-Term Debt Issuance | 13.52M |
| Long-Term Debt Payments | -364,000 |
| Other Financing Charges | — |
| Financing Cash Flow | 13.15M |
| Other Cash Details | |
| End Cash Position | 5.36M |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -10.00M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|
Article
BioHarvest Sciences appoints veteran technology leader to board of directors
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) has announced the appointment of seasoned technology executive Sharon Malka as an independent director of the company. Malka brings extensive leadership experience to BioHarvest, with a background spanning international healthcare and technology companies.
Jan 22, 2025
Article
BioHarvest Announces Appointment of Sharon Malka to Board of Directors
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest.
Jan 22, 2025
Article
BioHarvest Sciences positioned for ‘legacy year' in 2025, building on momentum with new innovations and strategic collaborations
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) is poised to capitalize on key trends shaping the health and wellness industry in 2025, including a growing focus on sustainability, longevity-driven health solutions, and plant-based innovation. “The notions of sustainability, longevity, and the recognition of the power that exists in plants from consumers and industry are three critical trends that are really driving tailwinds,” Ilan Sobel, BioHarvest Sciences CEO, told Proactive.
Jan 20, 2025
